XPF expression correlates with clinical outcome in squamous cell carcinoma of the head and neck.

ABSTRACT:

Purpose

Tumor-specific biomarkers that predict resistance to DNA damaging agents may improve therapeutic outcomes by guiding the selection of effective therapies and limiting morbidity related to ineffective approaches. XPF (ERCC4) is an essential component of several DNA repair pathways and XPF-deficient cells are exquisitely sensitive to DNA damaging agents. The purpose of this study was to determine whether XPF expression levels predict clinical response to DNA damaging agents in head and neck squamous cell carcinoma (HNSCC).

Experimental design

Quantitative immunohistochemistry was used to measure XPF expression in tumors from a cohort of 80 patients with newly diagnosed HNSCC treated with radiation therapy with or without platinum-based chemotherapy; samples were collec

SUBMITTER: Vaezi A 

PROVIDER: S-EPMC3156890 | biostudies-literature | 2011 Aug

REPOSITORIES: biostudies-literature